Welcome Contact

TEL: +86-1528 0268 510

Email: sales@sex-pharm.com

ADD: 0805, No. 24, Dongming Rd, Xiamen, China.

Fnose--Specifically R&D for heart disease!

Consignment note

  Scott Alba, USA, order No.:SE806901 has been shipped.

  Peter Alexander, USA, order No.:SE806907 has been shipped.

  Darren Brown, GB, order No.:SE806911 has been shipped.

  Yehudi Ben, USA, order No.:SE806942 has been shipped.

  Xavier naidoo, ES, order No.:SE806939 has been shipped.

  Trevor Wright, IT, order No.:SE806969 has been shipped.

  Xavier Scott, USA, order No.:SE806949 has been shipped.

  Wythe Gino, FR, order No.:SE806937 has been shipped.

  Dick Gaby, DE, order No.:SE806958 has been shipped.

  Derrick, DE, order No.:SE807039 has been shipped.

  Xenos Timothy, USA, order No.:SE807136 has been shipped.

  Ximen Vern, USA, order No.:SE807145 has been shipped.

  Udeh Vernon, KR, order No.:SE807255 has been shipped.

  Ulrich Warren, KR, order No.:SE807265 has been shipped.

  Leif Stuart, MY, order No.:SE807368 has been shipped.

  Lynn Randall, MY, order No.:SE807439 has been shipped.

  Louis Patrick, USA, order No.:SE807440 has been shipped.

  Levi Matthew, USA, order No.:SE807521 has been shipped.

  Dana Lorin, USA, order No.:SE807611 has been shipped.

  York green, GB, order No.:SE807739 has been shipped.

Related Products

Effects Of Once-Daily Tadalafil On Erectile Function

Men with benign prostatic hyperplasia (BPH) often sustain lower urinary tract symptoms (LUTS or BPH-LUTS) such as urinary frequency, urgency, intermittency, nocturia, straining, incomplete emptying, or weak urinary stream. BPH-LUTS and erectile dysfunction (ED), both highly prevalent conditions in aging men, may have common pathophysiological mechanisms, and contribute negatively to quality of life.

Phosphodiesterase type 5 (PDE5) isozymes are thought to be promising targets for drug intervention in the urogenital tract, and the potential use of PDE5 inhibitors as treatment for both BPH-LUTS and ED is of clinical interest. The PDE5 inhibitor tadalafil, currently approved for the treatment of erectile dysfunction and for the treatment of pulmonary arterial hypertension in some geographies, is being studied in men with signs and symptoms of BPH. Tadalafil is suitable for once-daily therapy due to its 17.5-hour half-life.

Back Homepage